(Q47786408)

English

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine

scientific article published on 10 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine (English)

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Alzheimer's disease

0 references

Martin R. Farlow

3

object named as

Martin R Farlow

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

author name string

Rachelle S Doody

1

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

David S Geldmacher

2

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Yijun Sun

4

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Margaret Moline

5

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Joan Mackell

6

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

publication date

10 May 2012

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Dementia and Geriatric Cognitive Disorders

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

33

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

2-3

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

164-173

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Treatment options in Alzheimer's disease: maximizing benefit, managing expectations

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis.

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Long-term course and effectiveness of combination therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile

1 reference

https://api.crossref.org/works/10.1159%2F000338236

21 January 2018

Identifiers

10.1159/000338236

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

1 reference

Europe PubMed Central

5 February 2018

http://europepmc.org/abstract/MED/22572767

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47786408&oldid=2170715047"